Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

Inclusion Criteria: * Signed informed consent prior to the study, fully understood the study content, procedures and potential adverse reactions; able to complete the study per protocol requirements. * The participant (including partner) agrees not to plan pregnancy, sperm donation or egg donation from screening until 6 months after the last study drug administration, and is willing to use effective contraception. * Healthy male and female participants aged 18-45 years (inclusive). * Male body weight ≥ 50.0 kg; female body weight ≥ 45.0 kg.BMI = weight (kg)/height² (m²), range 18.0-28.0 kg/m² (inclusive). Exclusion Criteria: * Participants with clinically significant abnormalities in vital signs, physical examination, ECG or clinical laboratory tests, and deemed unsuitable for participation by the investigator. * Participants with severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematologic, endocrine/metabolic, neoplastic, immune or psychiatric systems within the past 1 year or currently, or any other disease that may interfere with study results. * Platelet count or absolute neutrophil count below the lower limit of the reference range at screening. * Any disease increasing bleeding risk, such as hemorrhoids, acute gastritis, gastric or duodenal ulcer. * Alanine aminotransferase (ALT) \> 1.2×ULN, aspartate aminotransferase (AST) \> 1.2×ULN, alkaline phosphatase (ALP) \> 1.2×ULN, total bilirubin (TBIL) \> 1.2×ULN, or any clinically …